BTIG Maintains Buy on Medtronic, Lowers Price Target to $99

Benzinga Newsdesk www.benzinga.com Neutral 58.2%

Neg 0% Neu 58.2% Pos 0%

BTIG analyst Ryan Zimmerman maintains Medtronic (NYSE:MDT) with a Buy and lowers the price target from $100 to $99.

Comments

No comments yet. Be the first!